Sk Biopharmaceuticals Co., Ltd. · KRX:326030
Sk Biopharmaceuticals — Q2 2026 Earnings Presentation
8 slides from Sk Biopharmaceuticals's earnings presentation, Aug 5, 2026
Slide 1: SK Biopharmaceuticals 2026 Q2 Financial Results
SK Biopharmaceuticals 2026 Q2 Financial Results 2026.8.5
Slide 2: Disclaimer
Disclaimer • The financial information in this document is consolidated earnings results based on K-IFRS. • This document is intended for investor convenience only and is provided prior to the completion of the external audit of financial results. Final audit outcomes may result in adjustments to co
Slide 3: Q2 2026 Financial Results Highlights
Q2 2026 Financial Results Highlights ‣ XCOPRI® sales reached $149.5M; H1 sales totaled $284.5M, representing 49–52% of FY guidance $550–580M ‣ Strong XCOPRI® growth more than offset lower one-off revenue and higher SG&A, driving another record operating profit1) Quarterly Results XCOPRI® • Q2 XCOPRI
Slide 4: Q2 2026 Financial Results
Q2 2026 Financial Results [Consolidated] 2025 2026 [in KRW bn] QoQ YoY Q1 Q2 Q3 Q4 Annual Q1 Q2 Revenue 144.4 176.3 191.7 194.4 706.7 227.9 247.4 +8.5% +40.3% 133.3 154.1 172.2 170.8 630.3 197.7 224.4 +13.5% +45.6% XCOPRI® US¹ ($91.7M) ($109.5M) ($124.0M) ($117.9M) ($443.2M) ($135.0M) ($149.5M) (+10
Slide 5: XCOPRI US Prescriptions and Sales
XCOPRI® US Prescriptions and Sales ‣ Q2 TRx rebounded following the Q1 business-day impact, with June TRx reaching 49K ‣ New DTC campaign launched at end-June; expanding HCP and patient marketing to support continued growth in H2 3rd generation ASM TRx Trend XCOPRI® Monthly TRx XCOPRI® Quarterly Sal
Slide 6: Pipeline
Pipeline ‣ NDA for Cenobamate oral suspension submitted in Mar. 2026; sNDA filings for PGTC and pediatric expansion within 2026 ‣ Early-stage CNS, RPT and TPD pipelines progressing as planned; AI discovery collaboration with Insilico expands early-stage pipeline Indication Compound Discovery Pre-cli
Slide 7: Roadmap to Big Biotech
Roadmap to Big Biotech ‣ Leveraging Cenobamate-generated cash flow to build differentiated R&D platforms and a sustainable pipeline engine Early-Stage Pipeline Overview SKL35501 SKL37321 Chelator Small Molecule Leveraging medicinal chemistry expertise from SKL32276 (FL-091) (WT-7695) ROR1 Platform S
Slide 8: Slide 8
SK Biopharmaceuticals — Q2 2026 Earnings Presentation on 6ix